Johnson & Johnson

Johnson & Johnson (JNJ) sits near the top of its 52-week range at $276.47, with shares up sharply from the $173.33 low. The stock carries a P/E of 29.93, a premium that looks less rich against a 21.5% net margin but harder to justify with EPS down 7.8% year over year. Revenue grew 8.1%, so the earnings decline is cost-driven, not demand-driven. The Alpha Score of 47.4 reflects a neutral momentum read, with value at 48.2 and quality at 59.3; sentiment sits at 50. The gap between the quality score and the overall number suggests the market is paying for the franchise, not the current quarter. Watch the next earnings call for margin guidance, since the 8.1% top-line growth has yet to translate into profit growth. A narrower P/E would follow if the company holds costs in check.

Johnson & Johnson trades near the middle of its $173.33-$276.47 52-week range, with a P/E of 29.93 and net margin of 21.5%. Revenue grew 8.1% year over year, but EPS slipped 7.8%, compressing the earnings story behind the multiple. The Alpha Score of 47.4 reflects a split: quality scores 59.3 and sentiment 50, while value comes in at 48.2. Momentum is null, indicating no recent catalyst has shifted the stock's trajectory. The quality sub-score above 50 suggests the business generates consistent returns, yet the negative EPS growth and modest value reading give investors little reason to re-rate the stock higher at current levels. Watch for next quarter's revenue breakdown and any update on the consumer health spin-off timeline, both of which could nudge sentiment.

Johnson & Johnson (JNJ) reported revenue growth of 8.1% year over year, but earnings per share fell 7.8% in the same period. The divergence leaves the stock trading at 29.93 times trailing earnings, with a net margin of 21.5% and an EPS of $8.62. Shares sit well off their 52-week high of $276.47, near the lower half of a range that bottoms at $173.33. The Alpha Score of 47.4 reflects a neutral momentum reading, with value at 48.2, quality at 59.3, and sentiment at 50. The quality sub-score, while the strongest of the four, still sits below 60. Revenue growth outpaces the EPS contraction, but the margin compression that drove the bottom-line decline is the number to watch. Next week, investors will look for commentary on pricing power and pipeline updates to see whether the earnings slide is a one-quarter event or the start of a trend. The 52-week low remains a key support level if the stock extends its slide.

Johnson & Johnson (JNJ) reported a 7.8% year-over-year EPS decline to $8.62, even as revenue grew 8.1%. Net margin held at 21.5%, but the earnings drop pushed the stock's Alpha Score to 47.4, with momentum neutral and value at 48.2. The shares trade near the lower end of their 52-week range, which spans $173.33 to $276.47, at a P/E of 29.93. The quality sub-score of 59.3 suggests the margin pressure stems from costs rather than operations. Investors will watch whether the company can translate its revenue momentum into profit growth in the coming quarters. Next week's earnings call should clarify the drivers behind the EPS decline and any guidance for the rest of the year.

Johnson & Johnson trades at a P/E of 29.93, above the broader market, with trailing EPS of $8.62. Revenue grew 8.1% year over year, but EPS fell 7.8%, reflecting margin compression. Net margin remains healthy at 21.5%. The Alpha Score of 47.4 is held back by a null momentum reading and a value score of 48.2. Quality scores best at 59.3, while sentiment sits at 50. The stock sits near the middle of its 52-week range, having recovered from the $173 low but still well off the $276 high. Next quarter's earnings will show whether revenue growth can translate into EPS recovery or if cost pressures persist.